Novartis Reports Acquisition of SanReno Therapeutics to Advance Transformative Medicines for Kidney Disease
Shots:
- Through the acquisition of SanReno, Novartis obtains exclusive rights in Greater China and Singapore for two late-stage assets, atrasentan and zigakibart, for IgA Nephropathy (IgAN). SanReno investor and Chinook (now Novartis) has a JV established in 2021
- The P-III study is currently evaluating atrasentan (oral), an endothelin A receptor antagonist (ERA) for IgAN, which showed a clinically meaningful and significant reduction in proteinuria at the 36wks. interim analysis
- Zigakibart (SC), mAb developed to target 'A Proliferation Inducing Ligand' (APRIL), is presently under P-III trial evaluation following China's CDE approval in Oct 2023
Ref: PR Newswire | Image: SanReno Therapeutics
PharmaShots! Your go-to media platform for customized news ranging for multiple indications. For more information connect with us at connect@pharmashots.com
Click here to read the full press release
Tags
Shivani is a content writer at PharmaShots. She has a keen interest in recent innovations in the life sciences industry. She covers news related to Product approvals, clinical trial results, and updates. She can be contacted at connect@pharmashots.com.
